ZymoGenetics (ZGEN)

[surf1944]

ZymoGenetics skin cancer drug meets study goal

On Monday June 7, 2010, 7:28 am
NEW YORK (AP) -- A potential skin cancer treatment from ZymoGenetics met key goals in a midstage study, the company said.

The company said 23.1 percent of the skin cancer patients had an overall response and a median survival rate of 4.3 months without the disease progressing. The study focused on the drug Interleukin 21 and involved 40 patients.

ZymoGenetics Inc., based in Seattle, announced the results Saturday and presented them at the annual meeting of the American Society of Clinical Oncology in Chicago.